MedTrace Logo

Study of Picibanil (OK432) Sclerotherapy in Children With Macrocystic Lymphatic Malformations

NCT00010452 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2015-03-25

No results posted yet for this study

Summary

OBJECTIVES:

I. Determine the efficacy of picibanil sclerotherapy in children with macrocystic lymphangioma.

Conditions

  • Lymphatic Malformations

Interventions

DRUG

picibanil

Up to .2 mg per injection, given intralesionally every 6-8 weeks

Sponsors & Collaborators

  • University of Iowa

    lead OTHER

Principal Investigators

  • Richard J Smith · University of Iowa

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
6 Months
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2000-04-30
Primary Completion
2006-06-30
Completion
2007-11-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00010452 on ClinicalTrials.gov